Drug intelligence / Profile preview

SLV-313 SR

Development stage: Discontinued
Lead developer: Abbott
Modality: Small Molecules
Administration: Oral

Overview

SLV-313 SR is a sustained-release oral formulation of the investigational antipsychotic compound SLV-313 (also known as Adoprazine). It acts as a full agonist at the serotonin 5-HT1A receptor and as an antagonist at dopamine D2 and D3 receptors. The drug was developed for the treatment of schizophrenia and schizoaffective disorder, with additional potential indications in bipolar disorder and major depressive disorder with psychotic features. The mechanism of action—combining serotonergic agonism with dopaminergic antagonism—aims to provide antipsychotic efficacy while minimizing extrapyramidal side effects commonly associated with traditional antipsychotics[1][2][4].

Other names: Adoprazine

Targets

DRD3 (Dopamine receptor D3)DRD2 (Dopamine D2 Receptor)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))

Beyond the preview

Go deeper on SLV-313 SR.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SLV-313 SR.

Explore the full profile